R&D products

After having developed Fabenflu®, a product indicated for the treatment of avian influenza (H5N1) in human, Fab’entech is currently focusing on 3 products: a candidate targeting Ebola virus having been identified by the WHO as the unique therapeutic solution in Europe in 2014, a biodefense candidate developed in collaboration with the French army, and a new antidote program recently started in the field of drug intoxications.
​​

ANTIDOTES

Fab’entech is developing a core antidotes range leaded by its 2 products currently in development, and is seeking industrial partners to distribute these products at short-term. 

​Antidotes include immunotherapies targeting bioterrorism threats such as anthrax, and intoxications caused by venoms or drugs.

SEVERE infectious diseases

Fab’entech is looking for industrial partners to co-develop emergency immunotherapies targeting severe infectious diseases. 

​Severe infectious diseases include but are not limited to nosocomial infections such as Staphylococcus aureus.

EMERGING INFECTIOUS DISEASES

After having developed Fabenflu®, a product indicated for the treatment of avian influenza (H5N1) in human, Fab’entech is currently developing an emergency immunotherapy targeting Ebola virus with the support of renowned academic partners and the European Commission under the consortium IF-Ebola. Fab’entech is also member of a public-private consortium dedicated to Crimean-Congo Hemorrhagic Fever (CCHF), with the support of BPI France & Grand Lyon. Fab'entech remains open to new collaborations with academic partners & public institutions for the development of immunotherapies indicated for the treatment of emerging infectious diseases.

​Emerging infectious diseases also include: Mers-CoV, Hendra-Nipah, Lassa, Marburg, Dengue, Yellow Fever, West Nile, SRAS, etc.